
TABLE OF CONTENTS

SUMMARY	i
SUMMARY IN GERMAN (ZUSAMMENFASSUNG)	iii
LIST OF ABBREVIATIONS	v
TABLE OF CONTENTS	1
1.0. INTRODUCTION	5
1.1. The Intestinal immune system	5
1.1.1 The intestinal epithelial cells (IECs)	7
1.2. The involvement of probiotics in gastrointestinal immunity	11
1.3. <i>Enterococcus faecium</i>	13
1.4. Salmonellosis	14
1.4.1. Pathogenesis of <i>Salmonella</i>	15
1.4.2. Host defence against salmonellosis	17
1.5. Transmissible gastroenteritis virus (TGEV)	18
1.6. A closer look at selected receptors, enzymes, cytokines and inhibitors	21
1.6.1. Receptors	21
1.6.2. Enzymes	23
1.6.3. Cytokines	25
1.6.4. Inhibitors	28
1.7. Objectives of the study	29
2.0. MATERIALS AND METHODS	30
2.1. Materials	30
2.1.1. Experimental animals	30
2.1.2. Microorganisms	30
2.1.2.1. Probiotic: <i>Enterococcus faecium</i> SF 68 (NCIMB 10415) ---	30
2.1.2.2. <i>Salmonella typhimurium</i> DT 104	30
2.1.2.3. Transmissible gastroenteritis virus (TGEV)	30
2.1.3. Reagents.....	31
2.1.4. Kits.....	33
2.1.5. Enzymes.....	33
2.1.6. Antibodies	33
2.1.7. Consumables	34
2.1.8. Instruments	35

2.1.9. Solutions	36
2.2. <i>In-vivo</i> evaluation of the effect of <i>E. faecium</i> SF68 against <i>Salmonella typhimurium</i> DT 104	38
2.2.1. Experimental design	38
2.2.2. Animal feed	39
2.2.3. Infection with <i>S. typhimurium</i> DT 104	39
2.2.4. Collection of intestinal sections, spleen and blood	41
2.2.5. Isolation of lymphocytes from spleen, discrete and distal continuous PP	42
2.2.6. Isolation of intraepithelial lymphocytes from jejunum	43
2.2.7. Isolation of PBMC from Blood	43
2.2.8. Flow cytometry	44
2.2.8.1. Principle and application	44
2.2.8.2. Flow cytometric staining and phenotyping	46
2.2.9. Magnetic activated cell sorting (MACS)	47
2.2.10. Relative quantification of selected genes using Real-time PCR	49
2.2.10.1. Principles of real-time PCR	49
2.2.10.2. RNA isolation and cDNA synthesis	50
2.2.10.3. Primer design	51
2.2.10.4. Reverse transcription polymerase chain reaction (RT-PCR)	52
2.2.10.5. Real-time PCR measurement and analysis	52
2.3. <i>In-vitro</i> Evaluation of the effect of <i>E. faecium</i> SF68 against TGEV	53
2.3.1. Isolation of cells	53
2.3.2. Growth and cell- size characterization of Type I and Type II cells	54
2.3.2.1. Growth of Type I and Type II cells in Three-dimensional (3D) Culture	54
2.3.3. Transmission Electron Microscopy (TEM)	55
2.3.4. Flow cytometric and histochemical analysis of expression of cell markers	56
2.3.4.1. FACS Analysis	56
2.3.4.2. Confocal fluorescent microscopy	56
2.3.5. Analysis of Gene-Expression	57
2.3.5.1. Reverse transcription polymerase chain reaction	

(RT-PCR) -----	57
2.3.6. Determination of the sensitivity of type I and type II cells to TGEV Infection -----	58
2.3.7. Evaluation of the effect of the probiotic against TGEV infection in Type II cells -----	59
2.3.7.1. Virus -----	59
2.3.7.2. TCID ₅₀ determination -----	59
2.3.7.3. Methylthiazol-diphenyltetrazolium bromide (MTT) Test -----	60
2.3.7.4. Virus titre (TCID ₅₀) determination -----	61
2.3.7.5. Determination of cytokine modulation by the probiotic Bacteria -----	61
2.3.7.5.1. Pre-treatment and harvest of cells after virus infection-----	61
2.3.7.5.2. Total RNA extraction and reverse transcription---	61
2.3.7.5.3. Real time PCR -----	62
3.0. RESULTS -----	63
3.1. <i>In-vivo</i> Evaluation of the effect of <i>E. faecium</i> SF68 against <i>S. typhimurium</i> DT 104 -----	63
3.1.1. Percentages of CD8 and CD4 positive lymphocytes in the probiotic and control groups -----	63
3.1.2. Percentages of CD4 positive lymphocytes in the probiotic and control Groups -----	64
3.1.3. Isolation of CD4+ and CD8+ lymphocytes by MACS -----	65
3.1.4. IL-1 gene expression in PBMC -----	67
3.1.5. IL-8 gene expression in PBMC -----	68
3.1.6. TLRs gene expression in PBMC-----	69
3.1.7. IL-1ra gene expression in PBMC -----	70
3.1.8. TGF-β and CD9 gene expressions in PBMC -----	71
3.1.9. IL-1α gene expression in distal continuous PP -----	72
3.2. <i>In-vitro</i> Evaluation of the effect of <i>E. faecium</i> SF68 against TGEV -----	73
3.2.1. Difference of Type I and Type II cells in cell-size and growth rate ---	73
3.2.2. Overviews of type I and type II cells under the Transmission Electron Microscope (TEM) -----	76

3.2.3. The ultra-structures of type I and type II cells	77
3.2.3.1. The Microvilli	77
3.2.3.2. Cell-to-cell contact	77
3.2.3.3. Organelles	79
3.2.4. Studies on the expression of selected genes in type I and type II cells	81
3.2.5. Flow cytometric and histochemical analysis of expression of cell markers	82
3.2.5.1. FACS analysis for CD14 and CD45 markers in type I and type II cells	82
3.2.5.2. FACS analysis for endothelial markers	83
3.2.5.3. Detection of an epithelial cell marker using Fluorescence Microscopy	84
3.2.6. Sensitivity of type I and type II cells to TGEV infection	85
3.2.7. Detection of TGEV in type II cells using transmission electron Microscopy	86
3.2.8. Antiviral effect of the probiotic pre-treatment on the survival of type II and ST cells after TGEV infection	87
3.2.9. Antiviral effect of the probiotic pre-treatment on virus titre from type II Cells after TGEV infection	88
3.2.10. Effects of the probiotic pre-treatment on the expression of cytokines in type II cells	89
4.0. DISCUSSION	91
4.1. <i>In-vivo</i> Evaluation of the effect of <i>E. faecium</i> SF68 against <i>Salmonella typhimurium</i> DT 104	91
4.2. <i>In-vitro</i> Evaluation of the effect of <i>E. faecium</i> SF68 against TGEV	94
5.0. CONCLUSION	101
6.0. REFERENCES	108
ACKNOWLEDGEMENTS	120
LIST OF PUBLICATIONS	122
CURRICULUM VITAE	124